iRhythm price target lowered to $155 from $214 at Citi

Citi analyst Joanne Wuensch lowered the firm’s price target on iRhythm (IRTC) to $155 from $214 and keeps a Buy rating on the shares. The firm adjusted targets in the medical technology group as part of a Q1 preview. The “walls of worry are high” into the earnings reports with the sector undergoing significant multiple compression, the analyst tells investors in a research note. Citi removed iRhythm and Medtronic as top picks. The firm’s top picks are now Edwards Lifesciences and Intuitive Surgical.